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Sustained delivery of analgesic agents at target sites remains a critical issue for effective
pain management.The use of nanocarriers has been reported to facilitate effective delivery
of these agents to target sites while minimizing systemic toxicity. These include the
use of biodegradable liposomal or polymeric carriers. Of these, liposomes present as an
attractive delivery system due to their ﬂexible physicochemical properties which allow easy
manipulation in order to address different delivery considerations. Their favorable toxicity
proﬁles and ease of large scale production also make their clinical use feasible. In this
review, we will discuss the concept of using liposomes as a drug delivery carrier, their in
vitro characteristics as well as in vivo behavior. Current advances in the targeted liposomal
delivery of analgesic agents and their impacts on the ﬁeld of pain management will be
presented.
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INTRODUCTION
Targeted drug delivery provides effective, precise, and safe ther-
apeutic interventions for treatment of diverse disease conditions,
by limiting toxic side effects and/or increasing drug action. Effec-
tive drug targeting depends on several factors that are either
carrier or target related. The drug carrier must be stable, pro-
tect the drug from degradation, protect the body from harmful
side effects, and allow delivery to the target cell population in
vivo (Koning et al., 2002). The target must be well accessible for
the drug-targeting system and must display speciﬁc cell-surface
molecules that allow selective targeting and efﬁcient drug deliv-
ery (Vingerhoeds et al., 1994; Willis and Forssen, 1998; Ding et al.,
2006). The ﬁeld of site-speciﬁc drug delivery has been contin-
uously explored to develop formulations with a therapeutically
acceptable degree of target speciﬁcity. Many different approaches
using various physical and biochemical principles have been pro-
posed and examined, with targeted liposomes as a carrier for
both hydrophobic and hydrophilic drugs having attracted much
attention.
LIPOSOMES AS DRUG DELIVERY CARRIERS
Liposomes have long been considered good candidates for efﬁ-
cient drug carrier and delivery systems. They have been used
as delivery vehicles for stabilizing drugs, overcoming barriers
to cellular and tissue uptake, and for directing their contents
toward speciﬁc sites in vivo (Senior, 1987; Oku and Namba,
1994; Vingerhoeds et al., 1994; Woodle et al., 1994; Torchilin,
1996; Willis and Forssen, 1998; Bendas, 2001; Maruyama, 2002;
Moghimi and Szebeni, 2003; Metselaar and Storm, 2005; Ding
et al., 2006). The unique ability of liposomes to entrap drugs
both in an aqueous and a lipid phase make such delivery systems
attractive for hydrophilic and hydrophobic drugs. Hydropho-
bic molecules are intercalated within the bilayer membrane, and
hydrophilic molecules can be entrapped in the internal aqueous
region. Additionally, by virtue of their large aqueous interior and
biocompatible lipid exterior, they offer a possible means of local
delivery of a large variety of drug structures, from small molecules
tomacromolecules such as proteins andDNA, to the site of interest
while reducing systemic toxicity (Senior, 1987; Oku and Namba,
1994; Torchilin, 1996; Ulrich, 2002; Sahoo and Labhasetwar, 2003;
Ding et al., 2006).
Liposomes offer several advantages over other delivery systems.
Liposomes are generally considered non-toxic, biodegradable, and
non-immunogenic, as they are typically composed of naturally
occurring lipids. Association of a drug with liposomes generally
prolongs circulation half-life, reduces volume of distribution, and
lowers systemic toxicity. Moreover, the drug is protected from
early degradation, inactivation, and dilution in circulation (Oku
and Namba, 1994; Torchilin, 1996; Laverman et al., 1999; Ulrich,
2002; Sahoo and Labhasetwar, 2003). In vivo behavior of lipo-
somes can be easily modiﬁed by changing their characteristics,
such as size, lipid composition, and charge (Senior, 1987; Oku
and Namba, 1994; Willis and Forssen, 1998; Laverman et al., 1999;
Ulrich, 2002). In addition, the liposome surface can be modi-
ﬁed with polymer structures such as poly(ethylene glycol) (PEG),
which inhibits macrophage uptake and thereby increases liposome
circulation time, and with targeting moieties such as antibod-
ies or peptides (Senior, 1987; Oku and Namba, 1994; Torchilin,
1994;Woodle et al., 1994; Maruyama, 2002; Moghimi and Szebeni,
2003). Site-directing ligands incorporated into the liposomemem-
brane surface therefore have been investigated intensely in an
effort to further enhance the selectivity of liposomal drug delivery
(Sawant and Torchilin, 2012; Allen and Cullis, 2013; Koshkaryev
et al., 2013). Unlike solid polymeric carrier systems, liposome
membranes are dynamic structures, allowing surface-coupled lig-
ands a greater degree of freedom with the ability to move about
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within the bilayer plane, positioning themselves for optimal sub-
strate interactions (Willis and Forssen, 1998). Critical factors
for successful in vivo delivery of ligand-targeted liposomes will
involve selection of accessible and appropriate targets, use of lig-
ands with adequate selectivity and afﬁnity for these targets, and
suitable liposome surface coupling methods for correct presen-
tation of ligands to their binding sites (Vingerhoeds et al., 1994;
Torchilin, 1996; Willis and Forssen, 1998; Metselaar and Storm,
2005; Ding et al., 2006). The beneﬁt of liposomes as therapeutic
carriers stimulates the accumulation of novel experiences in the
practical aspects of liposomes, aswell as newdevelopments in basic
research.
IN VIVO STABILITY, BIODISTRIBUTION, AND
BIOAVAILABILITY OF LIPOSOMES
Several major hurdles must be overcome in order to prolong
liposome circulation times. These include stabilizing the vesi-
cles against leakage of entrapped contents, avoiding opsonization,
and minimizing removal by the reticuloendothelial system (RES;
Willis and Forssen, 1998). The rate at which liposomes are cleared
depends on their size, surface charge, and stability (Oku and
Namba, 1994; Laverman et al., 1999; Ishida et al., 2001; Ulrich,
2002). The presence of a high electrostatic surface charge pro-
motes the interaction of liposomes with biomolecules that could
serve as opsonins andwith cells (Laverman et al., 1999; Ishida et al.,
2001). In general, unmodiﬁed large liposomes are cleared more
rapidly than small, neutral, or positively charged liposomes (Oku
and Namba, 1994; Laverman et al., 1999; Ishida et al., 2001; Ulrich,
2002). Previous studies have demonstrated that the liver removes
large, charged liposomes rapidly, with spleen clearance half-life
of less than 1 h (Chrai et al., 2002). The presence of cholesterol is
another important factor both for enhancing stability against leak-
age and in minimizing phospholipid exchange (Willis and Forssen,
1998; Laverman et al., 1999). This minimizes lipid exchange with
other structures in the circulation (red blood cells, lipoproteins),
which can lead to depletion of the high phase transition temper-
ature lipids and their replacement with less physiologically stable
components (Willis and Forssen, 1998; Laverman et al., 1999;
Ulrich, 2002).
A major concern in using liposomes for therapeutic purposes
is their fast removal from blood circulation by components of the
RES. The RES is the major site of liposome accumulation after sys-
temic administration. Primary organs associated with the RES are
the liver, spleen, kidneys, lungs, bone marrow, and lymph nodes
(Senior, 1987; Oku and Namba, 1994; Vingerhoeds et al., 1994;
Ishida et al., 2001; Chrai et al., 2002). The liver exhibits the largest
capacity for uptake, whereas the spleen can accumulate liposomes
so that its tissue concentration is 10-fold higher than those of other
organs (Chrai et al., 2002). Removal of liposomes from the blood is
attributed to phagocytic cells that reside in theRES and ismediated
through direct interactions between those cells and the lipo-
somes (Senior, 1987; Oku and Namba, 1994; Vingerhoeds et al.,
1994; Ishida et al., 2001; Chrai et al., 2002). Although clearance
of liposomes by the RES occurs predominantly after opsoniza-
tion of the vesicles, that is the adsorption of plasma proteins
(e.g. immunoglobulins, ﬁbronectin, complement components,
C-reactive protein) onto their surface, in vitro studies have shown
that liposomal uptake into macrophages can also occur in the
absence of serum proteins (Ishida et al., 2001; Chrai et al., 2002).
The extent of opsonization decreases with a decrease in liposome
size from 800 to 200 nm in diameter (Chrai et al., 2002). Small
liposomes could not support opsonic activity, whereas the larger
ones did so substantially. The profound effect of size on comple-
ment recognition affects liver uptake, depending on the extent of
liposome opsonization (Laverman et al., 1999; Ishida et al., 2001;
Chrai et al., 2002). One of the major steps in improving circulation
time and preventing removal by RES was sterically stabilizing the
liposomes through the introduction of PEG modiﬁcation (Oku
and Namba, 1994; Torchilin, 1994, 1996; Vingerhoeds et al., 1994;
Woodle et al., 1994; Willis and Forssen, 1998; Maruyama, 2002;
Ulrich, 2002; Moghimi and Szebeni, 2003). More speciﬁcally,
stabilization of liposomes with PEG creates a local surface con-
centration of highly hydrated groups which sterically inhibits both
electrostatic and hydrophobic interactions with a variety of serum
proteins or cells, thus resulting in a reduced uptake by cells of the
RES (Ishida et al., 2001). Many targeting systems with promising
outlook based on in vitro results have faced the above problems
when tested in vivo (Sahoo and Labhasetwar, 2003). Therefore,
having an understanding of the events that take place in vivo
is essential for the design of particles with optimal circulation
proﬁles.
The accumulation of liposomes at the target site is a prerequi-
site but does not necessarily guarantee a therapeutic effect of the
encapsulated drug. Therefore, the crucial role of the liposome-cell
interaction has to be taken into account (Vingerhoeds et al., 1994;
Willis and Forssen, 1998; Ulrich, 2002). Multiple factors such as
activation state of the target cell or size, charge, sterical stabiliza-
tion, and pH-dependence of the liposomes have an important
impact on this interaction (Vingerhoeds et al., 1994; Willis and
Forssen, 1998; Laverman et al., 1999; Ulrich, 2002; Muro and
Muzykantov, 2005). The cellular incorporation of liposomal con-
tent can occur in different ways: (i) extracellular release of the
soluble content and uptake via diffusion or pore formation; (ii)
liposomal fusion within the cell membrane followed by an intra-
cellular release of the liposomal content; and (iii) active uptake
of the liposomes via an endocytotic or phagocytotic pathway
(Vingerhoeds et al., 1994; Willis and Forssen, 1998; Bendas, 2001;
Ulrich, 2002). In receptor-mediated endocytosis, small particles
(<150 nm diameter) bind to cell surface receptors and are taken
up by clathrin-coated pits to form coated vesicles. After internal-
ization, the clathrin coat is removed and the vesicle fuses with
lysosomes, which induces the breakdown of the lipids and release
of their contents. Large particles (>150 nm), on the other hand,
are taken up principally by phagocytosis, which is usually limited
to speciﬁc cells such as macrophages but can be induced in many
other cell types with appropriate ligands. In both cases, liposomes
could either be degraded in the low pH environment, or they
could fuse directly with the endosomal or lysosomal membrane
(Willis and Forssen, 1998; Ulrich, 2002). In addition, macro-
molecules can cross the endothelial barrier in three ways: (Koning
et al., 2002) between the cells, through cell junctions (paracellu-
lar); (Ding et al., 2006) through the endothelial cell, via pores;
and (Vingerhoeds et al., 1994) transcellularly, via shuttling vesicles
and speciﬁc receptors (van Hinsbergh, 1997; Antohe et al., 2004).
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It is generally believed that the charge and compactness of the
endothelial matrix contribute additionally to the selectivity of the
endothelial barrier toward molecules of different size and charge
(van Hinsbergh, 1997).
LIPOSOMES – THERAPEUTIC OPPORTUNITIES
The use of liposomes as drug sustained release systems or as drug
delivery systems for passive targeting is well established, with sev-
eral drug formulations in the clinic or in late clinical trials (Sawant
and Torchilin, 2012; Allen and Cullis, 2013; Koshkaryev et al.,
2013). Several laboratories have reported the use of liposomes
as drug carriers in the treatment of cancer, fungal diseases, and
inﬂammatoryor immunediseases (OkuandNamba,1994;Vinger-
hoeds et al., 1994; Woodle et al., 1994; Willis and Forssen, 1998;
Sahoo and Labhasetwar, 2003; Metselaar and Storm, 2005). Inno-
vative research in liposomal drugs has led to commercialization
of several liposomal formulations, including anticancer therapeu-
tics (Doxil® and Myocet®) and an antifungal drug formulation
(AmBisome®). These products have demonstrated improved ther-
apeutic indices over their corresponding conventional drugs by
avoiding sensitive tissues and/or increasing delivery to speciﬁc
targets in vivo (Oku and Namba, 1994; Vingerhoeds et al., 1994;
Willis and Forssen, 1998). Liposomes offer several advantages over
other delivery systems including biocompatibility, capacity for
self-assembly, ability to carry large payloads of active agent, and
a wide range of physical properties that can be modiﬁed to con-
trol their biological properties (Senior, 1987; Woodle et al., 1994;
Torchilin, 1996; Willis and Forssen, 1998; Bendas, 2001; Moghimi
and Szebeni, 2003). Additionally, the delivery system itself is
pharmacologically inactive with minimal toxicity, and is readily
metabolized and cleared from the circulation once its carrier func-
tion has been completed (Willis and Forssen, 1998). An advantage
that liposomes possess over solid particulate delivery systems is
their ability to transport and deliver biologically active molecules
without the need for covalent coupling (Willis and Forssen, 1998).
To improve upon these therapies, clinically active liposomal deliv-
ery systems may need to include site-directed surface ligands to
further enhance their selective delivery. The concept of drug tar-
geting and controlled drug delivery is used in attempts to improve
the therapeutic index of drugs by increasing their localization to
speciﬁc organs, tissues, or cells and by decreasing their activity
and potential toxic side effects in normal organs (e.g. heart, liver,
or kidneys). This concept is especially important for drugs with
a narrow therapeutic window which has the potential of having
detrimental effects (Vingerhoeds et al., 1994; Willis and Forssen,
1998; Bendas, 2001; Maruyama, 2002).
USE OF NANOCARRIERS FOR PAIN THERAPIES
Drug delivery systems have been used in pain therapies to improve
toxicity or side effect proﬁles by targeted delivery to speciﬁc sites
in the body, increase drug upload or bioavailability, and to pro-
vide prolonged drug release. For example, an area of interest has
been the delivery of opioid-based compounds to target periph-
eral opioid receptors within injured tissue to promote analgesic
and anti-inﬂammatory activity (Hua and Cabot, 2010). It is well-
established that many conventional opioid agonists have been
shown to produce potent opioid receptormediated analgesiawhen
administered locally into injured tissue of rodents, non-human
primates, and humans (Stein et al., 2001, 2003; Rittner and Stein,
2005; Rittner et al., 2005). However, with increased blood ﬂow
secondary to inﬂammation, drugs may still be absorbed into the
systemic circulation, leading to side effects mediated by activation
of central or peripheral opioid receptor activity (e.g., sedation,
respiratory depression, dependence, tolerance, nausea, or consti-
pation) (Stein et al., 2001, 2003; Menendez et al., 2005; Rittner
et al., 2005; Rittner and Stein, 2005; Sevostianova et al., 2005).
This area of research of applying targeted drug delivery and the
use of nanocarriers in the management of pain is a novel and excit-
ing area of research, with much potential for growth and clinical
beneﬁts. The remainder of the review will focus on the progress
made in this area of research in experimental and clinical studies
(Figure 1).
EXPERIMENTAL USE OF NANOCARRIERS FOR PAIN
THERAPIES
Nanosystems used for delivering compounds intended for pain
therapies, such as local anesthetics (de Paula et al., 2012) or non-
steroidal anti-inﬂammatory drugs (NSAIDS), have been reviewed
previously (Puglia et al., 2013). The encapsulation of local anes-
thetics into liposomes, for instance, presents advantages such
as slow release, prolonged duration of action, reduced plasma
concentrations, and low toxicity to the central nervous and car-
diovascular systems. A number of pre-clinical studies have been
conducted encapsulating local anesthetics, such as bupivacaine
or lidocaine, into multilamellar or unilamellar liposomes using
different phospholipid and pH combinations (de Paula et al.,
2012). These studies report increased duration of anesthesia and
sensory blockade following parenteral administration of these
formulations.
Targeted delivery of glucocorticosteroids has been widely stud-
ied for the treatment of rheumatoid arthritis and other inﬂam-
matory joint conditions (Metselaar et al., 2003, 2004; Metselaar
and Storm, 2005). Although corticosteroids are not classiﬁed as
an analgesic, the pain relieving effects are secondary to their
anti-inﬂammatory activity. Long-circulatingPEGylated liposomes
containing methylprednisolone or betamethasone have been used
to treat Lewis rats with adjuvant-induced arthritis (AIA) both at
early (before clinical signs appear) and late (at the peak of the
disease) stages of the disease (Avnir et al., 2008). In addition,
Ulmansky et al. (2012) showed that intravenous treatment with
sterically stabilized nano-liposomes (NSSL) encapsulated with
methylprednisolone or betamethasone signiﬁcantly decreased the
severity of adjuvant arthritis in Lewis rats throughout all disease
stages. They reported that both subcutaneous and intravenous
administration of glucocorticoid-encapsulated NSSL was able to
suppress arthritis signiﬁcantly compared to higher doses of the
free drugs or to TNF-α antagonists (Ulmansky et al., 2012).
Non-steroidal anti-inﬂammatory drugs have long been used
as an analgesic and anti-inﬂammatory agent. However, they are
associated with numerous interactions with other medications
and have serious side effects to the gastrointestinal tract, kid-
neys, and cardiovascular system (Rittner et al., 2005; Warner and
Mitchell, 2008). Nanocarriers have been used to enhance the efﬁ-
cacy and reduce the toxicity of NSAIDs by targeted delivery to
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FIGURE 1 | Use of nanocarriers for pain management.
the site of inﬂammatory pain. A number of topical and par-
enteral nano-formulations have been utilized and have shown
success in preclinical studies (Bansal et al., 2007; Rafﬁn et al.,
2012; Tart¸a˘u et al., 2012; Dong et al., 2013; Puglia et al., 2013).
Dong et al. (2013) recently demonstrated that celecoxib-loaded
liposomes embedded into hyaluronate gel was more effective
than either single agent in pain control and cartilage protection
in a rabbit knee osteoarthritis model following intra-articular
injection.
Targeted nanoparticles have recently been engineered to deliver
opioids, in particular loperamide HCl, speciﬁcally to periph-
eral opioid receptors to induce analgesic and anti-inﬂammatory
actions for use in painful inﬂammatory conditions (Hua and
Cabot, 2013). Loperamide is a peripherally-selective mu-opioid
receptor agonist that does not have analgesic effects follow-
ing intravenous or oral application due to its physicochemical
properties. These nanoparticles are conjugated with antibodies
targeted against intercellular adhesion molecule-1 (anti-ICAM-
1) which mimics the properties of opioid-containing immune
cells. These targeted nanoparticles produced highly signiﬁcant
analgesic and anti-inﬂammatory effects over the 48-h time
course studied following intravenous administration in rats
with Complete Freund’s Adjuvant-induced inﬂammation of the
paw. Biodistribution data demonstrated speciﬁc localization of
the targeted nanoparticles to peripheral inﬂammatory tissue
with no signiﬁcant uptake into the brain (Hua and Cabot,
2013). Other sustained release systems have also been engi-
neered to prolong the duration of action of opioid analgesics
(Ward et al., 2013).
A number of non-lipid-based nanocarrier formulations have
also been studied to improve the oral (Martín-Banderas et al.,
2012; Tang et al., 2012), intranasal (Kumar et al., 2013; Patel et al.,
2013), and CNS delivery of analgesic agents (Liu et al., 2006;
Tosi et al., 2007; Chen et al., 2013). Local or systemic adminis-
tration of endogenous opioid peptides (e.g. β-endorphin) is not
viable due to its short half-life in the blood and within inﬂamed
tissue. Liu et al. (2006) demonstrated that opioid peptides, in
particular endomorphin-1, adsorbed onto the surface of butyl-
cyanoacrylate nanoparticles and coated with polysorbate 80 could
penetrate the blood-brain barrier following intravenous admin-
istration to cause analgesia. Tosi et al. (2007) investigated the
in vivo antinociceptive efﬁcacy of peptide-derivatised nanopar-
ticles loaded with loperamide HCl for delivery to central opioid
receptors, and reported a peak percentage of maximum possi-
ble effect (% MPE) of 60% at 4 h and a signiﬁcant sustained
release effect for 6 h after tail vein injection of a dose equiva-
lent of 0.7 mg of loperamide HCl in Wistar rats. In addition,
Chen et al. (2013) showed that nanoparticles consisting of lop-
eramide and PLGA-PEG-PLGA triblock copolymer coated with
poloxamer 188 or polysorbate 80 had improved penetration
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across the blood-brain barrier in comparison toPLGA-PEG-PLGA
nanoparticles andPLGAnanoparticles. These studies demonstrate
that the use of surface modiﬁcation for nanoparticles is an efﬁ-
cient strategy to deliver opioid analgesics to speciﬁc sites in the
body.
CLINICAL USE OF NANOCARRIERS FOR PAIN THERAPIES
Although liposomes and nanoparticles present an exciting oppor-
tunity to improve the management of a variety of painful condi-
tions, current clinical use is limited and few products appear to be
in use for human clinical trials. Liposome encapsulation of local
anesthetics,NSAIDs, and opioids has been studied in humanswith
promising results. For example, liposomal formulations of local
anesthetics have been demonstrated to provide signiﬁcantly pro-
longed pain relief after surgical procedures and in chronic cancer
(de Paula et al., 2012). Gorﬁne et al. (2011) compared the magni-
tude and duration of postoperative analgesia from a single dose of
bupivacaine extended-release injection with placebo administered
intraoperatively via wound inﬁltration in 184 patients undergoing
hemorrhoidectomy in a multicenter, randomized, double-blind,
placebo-controlled trial. The results showed that the liposomal
formulation signiﬁcantly reduced pain over 72 h and decreased
opioid requirements, compared to placebo (Gorﬁne et al., 2011).
Similarly, Lafont et al. (1996) reported prolonged pain relief in a
patient with chronic cancer that lasted for 11 h after injection of
a liposomal bupivacaine formulation, compared to 4 h for plain
bupivacaine.
The efﬁcacy of topical liposomal NSAID-based formulations
has also been demonstrated in clinical studies (Puglia et al.,
2013). For example, indomethacin-loaded liposomes incorpo-
rated into hydrogels were studied in UVB-induced erythema on
healthy human volunteers. The results provided a more prolonged
anti-inﬂammatory effect in comparison to a gel formulation con-
taining free drug, allowing a sustained release of the drug to deeper
skin layers (Puglia et al., 2004).
Strategies to restrict the access of opioid agonists to the CNS
have also been of major interest in pain research (Menendez
et al., 2005; Sevostianova et al., 2005). With regards to incorpo-
ration of hydrophilic opioids into liposomal formulations, an
extended-release morphine preparation based on a multivesicu-
lar lipid suspension foam technology is available in the United
States (Rose et al., 2005; Viscusi et al., 2005). This preparation
is indicated for pain relief after major surgery (e.g., orthopedic
surgery involving lower extremities, lower abdominal surgery, or
cesarean delivery) as a single lumbar epidural injection. Stud-
ies have demonstrated effective, dose-related analgesia for up to
48 h after a single dose (Rose et al., 2005; Viscusi et al., 2005).
Although the safety proﬁle was largely consistent with those for
other epidurally administered opioid analgesics, systemic adverse
effects were still reported. In fact, the rate of respiratory depres-
sion was higher in the liposomal morphine group compared
with the intravenous patient controlled analgesia (PCA) fentanyl
group, which suggest that patient characteristics are important
in choosing an appropriate dose of liposomal morphine (Vis-
cusi et al., 2005). While beneﬁts were seen with its use following
cesarean section (Carvalho et al., 2007), another study showed
no beneﬁt over traditional opioids following abdominal surgery
with breakthrough pain relief still required and a similar side
effect proﬁle to traditional opioids (Gambling et al., 2005). To
date, the clinical studies for pain therapies have only investi-
gated the use of conventional liposomes which permits passive
targeting. It is anticipated that the use of ligand-targeted nanocar-
riers (active targeting) for pain therapies will further improve
the efﬁcacy and side effect proﬁle of the conventional liposome
formulations.
CONCLUSION
This phenomenon of disease-site targeting is believed to play a
major role in the enhanced efﬁcacy observed for a variety of drugs
when formulated inside lipid vesicles. Despite the clinical need, the
use of nano-based therapeutics to target and treat inﬂammation
and pain is only beginning to be exploited. The use of drug-loaded
liposomes for this application would be promising for a multitude
of acute and chronic pain conditions (e.g., post-operative pain,
visceral cancer pain, rheumatoid arthritis, or neuropathic pain).
Their use will ultimately lead to improved efﬁcacy, increased dura-
tion of action, and improved side effect proﬁle of analgesic and
anti-inﬂammatory therapeutics.
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